Resveratrol has demonstrated a wealth of promising benefits such as anti-aging, anti-inflammatory, and anti-diabetic effects, and further as a potent anti-viral and anti-neoplastic agent. Additionally, Resveratrol offers great potential as a cardiovascular disease modulating agent, as demonstrated by an abundance of pre-clinical trials related to heart disease. The phenomenon of “French Paradox”, the observation that French people suffer a relatively low incidence of coronary heart disease (despite having a diet that is relatively rich in saturated fats), has been attributed to the consumption of red wine that contains Resveratrol. Furthemore, historically, the medicinal use of herbs containing Resveratrol containing herbs has been known for a long time.
Severely limited availability of Resveratrol at potential sites of action may be one major explanation for the lack of chemopreventive effects of Resveratrol in vivo in humans as well as in animal models of human disease.
The metabolism of resveratrol has been shown to be very fast with the majority of biotransformation occurring within the first hour following oral administration. Resveratrol metabolites have very short half-life and are subjected to rapid urinary elimination.
SoluBest has applied its proprietary Solumer™ technology platform to obtain Resveratrol formulation with exceptional results. SoluBest's Resveratrol (Solu-RSV) demonstrate superior physico-chemical, PK, and PD properties compared to competitors.
Solubility Resveratrol is a water insoluble compound. It may be dispersed in water, however it immediately precipitates. Solu-RSV stays dispersed in a solution in a concentration as high as 1% for several hours.
Upon contact with water it self-disperses into uniform colloids. The mean particle size of Solu-RSV colloids is at a range of 0.5-5µm:
Product Structure SEM images demonstrate that SoluResveratrol is constructed from the porous polymer aggregates (100-200 mm) covered by submicron-micron particles of Resveratrol (0.5-5 mm).
Bioavailability As shown on healthy volunteers, Solu-RSV has a 4-5 fold higher bioavailability than the raw trans-RSV after oral administration. The level of metabolites detected in blood was 2 times higher.
Independent of food intake In addition to surpassing the dissolution profile, Solu-RSV has better performance in respect of food dependence, as was shown in the dissolution test performed in conditions modeling the fasted and fed states, where Solu-RSV's dissolution did not have a food effect.
Currently Solubest is completing final preparations for Solu-RSV production and marketing.